Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

A PHASE I/IIa TRIAL USING CD19-TARGETED THIRD GENERATION CAR T CELLS FOR LYMPHOMA AND LEUKEMIA.

Enblad G, Karlsson H, Gammelgard G, Wenthe J, Lovgren T, Amini RM, Wikstrom KI, Essand M, Savoldo B, Hallbook H, Höglund M, Dotti G, Brenner MK, Hagberg H, Loskog A.

Clin Cancer Res. 2018 Aug 10. pii: clincanres.0426.2018. doi: 10.1158/1078-0432.CCR-18-0426. [Epub ahead of print]

PMID:
30097433
2.

CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30+ and CD30- Embryonal Carcinoma via Antigen-dependent and Fas/FasL Interactions.

Hong LK, Chen Y, Smith CC, Montgomery SA, Vincent BG, Dotti G, Savoldo B.

Cancer Immunol Res. 2018 Aug 7. pii: canimm.0065.2018. doi: 10.1158/2326-6066.CIR-18-0065. [Epub ahead of print]

PMID:
30087115
3.

Adoptive Cell Therapy in Treating Pediatric Solid Tumors.

Tesfaye M, Savoldo B.

Curr Oncol Rep. 2018 Aug 1;20(9):73. doi: 10.1007/s11912-018-0715-9. Review.

PMID:
30069644
4.

Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy.

Pellegatta S, Savoldo B, Di Ianni N, Corbetta C, Chen Y, Patané M, Sun C, Pollo B, Ferrone S, DiMeco F, Finocchiaro G, Dotti G.

Sci Transl Med. 2018 Feb 28;10(430). pii: eaao2731. doi: 10.1126/scitranslmed.aao2731. Erratum in: Sci Transl Med. 2018 Apr 4;10 (435):.

PMID:
29491184
5.

Treating hematological malignancies with cell therapy: where are we now?

Landoni E, Savoldo B.

Expert Opin Biol Ther. 2018 Jan;18(1):65-75. doi: 10.1080/14712598.2018.1384810. Epub 2017 Oct 5. Review.

PMID:
28978241
6.

Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.

Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, Bollard CM, Chang BH, Rooney CM, Brenner MK, Heslop HE, Dotti G, Savoldo B.

J Clin Invest. 2017 Sep 1;127(9):3462-3471. doi: 10.1172/JCI94306. Epub 2017 Aug 14.

7.

Targeting Immune System Alterations in Hodgkin Lymphoma.

Grover NS, Savoldo B.

Curr Hematol Malig Rep. 2017 Aug;12(4):358-369. doi: 10.1007/s11899-017-0398-6. Review.

PMID:
28780614
8.

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.

Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, Gagea M, Banerjee P, Cai R, Bdaiwi MH, Basar R, Muftuoglu M, Li L, Marin D, Wierda W, Keating M, Champlin R, Shpall E, Rezvani K.

Leukemia. 2018 Feb;32(2):520-531. doi: 10.1038/leu.2017.226. Epub 2017 Jul 20.

PMID:
28725044
9.

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.

Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, Mehta B, Zhang H, Mahmood N, Tashiro H, Heslop HE, Dotti G, Rooney CM, Brenner MK.

Mol Ther. 2017 Sep 6;25(9):2214-2224. doi: 10.1016/j.ymthe.2017.05.012. Epub 2017 Jun 9.

PMID:
28602436
10.

Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.

Diaconu I, Ballard B, Zhang M, Chen Y, West J, Dotti G, Savoldo B.

Mol Ther. 2017 Mar 1;25(3):580-592. doi: 10.1016/j.ymthe.2017.01.011. Epub 2017 Feb 8.

11.

Immunotherapy in the Treatment of Human Solid Tumors: Basic and Translational Aspects.

Olive D, Savoldo B, Pastorino F, Castriconi R.

J Immunol Res. 2016;2016:7853028. doi: 10.1155/2016/7853028. Epub 2016 Jun 1. No abstract available.

12.

Glycolysis determines dichotomous regulation of T cell subsets in hypoxia.

Xu Y, Chaudhury A, Zhang M, Savoldo B, Metelitsa LS, Rodgers J, Yustein JT, Neilson JR, Dotti G.

J Clin Invest. 2016 Jul 1;126(7):2678-88. doi: 10.1172/JCI85834. Epub 2016 Jun 13.

13.

Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.

Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, Liu E, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Brenner MK, Heslop HE, Dotti G.

J Clin Invest. 2016 Jul 1;126(7):2588-96. doi: 10.1172/JCI86000. Epub 2016 Jun 6.

14.

Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.

Sun C, Dotti G, Savoldo B.

Blood. 2016 Jun 30;127(26):3350-9. doi: 10.1182/blood-2015-12-629089. Epub 2016 May 20. Review.

15.

Chimeric Antigen Receptors for Cancer Immunotherapy.

Geldres C, Savoldo B, Dotti G.

Methods Mol Biol. 2016;1393:75-86. doi: 10.1007/978-1-4939-3338-9_7.

PMID:
27033217
16.

Chimeric antigen receptor-redirected T cells return to the bench.

Geldres C, Savoldo B, Dotti G.

Semin Immunol. 2016 Feb;28(1):3-9. doi: 10.1016/j.smim.2015.12.001. Epub 2016 Jan 12. Review.

17.

Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.

Karlsson H, Svensson E, Gigg C, Jarvius M, Olsson-Strömberg U, Savoldo B, Dotti G, Loskog A.

PLoS One. 2015 Dec 23;10(12):e0144787. doi: 10.1371/journal.pone.0144787. eCollection 2015.

18.

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation.

Zhou X, Dotti G, Krance RA, Martinez CA, Naik S, Kamble RT, Durett AG, Dakhova O, Savoldo B, Di Stasi A, Spencer DM, Lin YF, Liu H, Grilley BJ, Gee AP, Rooney CM, Heslop HE, Brenner MK.

Blood. 2015 Jun 25;125(26):4103-13. doi: 10.1182/blood-2015-02-628354. Epub 2015 May 14.

19.

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.

Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, Heslop HE, Brenner MK, Rooney CM, Ramos CA.

Blood. 2015 Jun 18;125(25):3905-16. doi: 10.1182/blood-2015-01-621474. Epub 2015 May 4.

20.

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes.

Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, Ittmann MM, Marchetti D, Dotti G.

Nat Med. 2015 May;21(5):524-9. doi: 10.1038/nm.3833. Epub 2015 Apr 13.

21.

K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo.

Caruana I, Weber G, Ballard BC, Wood MS, Savoldo B, Dotti G.

Clin Cancer Res. 2015 Jul 1;21(13):2952-62. doi: 10.1158/1078-0432.CCR-14-2998. Epub 2015 Feb 17.

22.

Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy.

Perna SK, Huye LE, Savoldo B.

Immunotargets Ther. 2015 Mar 19;4:55-63. doi: 10.2147/ITT.S31389. eCollection 2015. Review.

23.

Survivin-specific T cell receptor targets tumor but not T cells.

Arber C, Feng X, Abhyankar H, Romero E, Wu MF, Heslop HE, Barth P, Dotti G, Savoldo B.

J Clin Invest. 2015 Jan;125(1):157-68. doi: 10.1172/JCI75876. Epub 2014 Nov 21.

24.

Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.

Nishio N, Diaconu I, Liu H, Cerullo V, Caruana I, Hoyos V, Bouchier-Hayes L, Savoldo B, Dotti G.

Cancer Res. 2014 Sep 15;74(18):5195-205. doi: 10.1158/0008-5472.CAN-14-0697. Epub 2014 Jul 24.

25.

High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells.

Wen J, Li H, Tao W, Savoldo B, Foglesong JA, King LC, Zu Y, Chang CC.

Br J Haematol. 2014 Sep;166(5):711-9. doi: 10.1111/bjh.12951. Epub 2014 May 29.

26.

Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.

Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, Liu H, Creighton CJ, Gee AP, Heslop HE, Rooney CM, Savoldo B, Dotti G.

Blood. 2014 Jun 12;123(24):3750-9. doi: 10.1182/blood-2014-01-552174. Epub 2014 Apr 29.

27.

Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene.

Zhou X, Di Stasi A, Tey SK, Krance RA, Martinez C, Leung KS, Durett AG, Wu MF, Liu H, Leen AM, Savoldo B, Lin YF, Grilley BJ, Gee AP, Spencer DM, Rooney CM, Heslop HE, Brenner MK, Dotti G.

Blood. 2014 Jun 19;123(25):3895-905. doi: 10.1182/blood-2014-01-551671. Epub 2014 Apr 21.

28.

CD19-CAR trials.

Ramos CA, Savoldo B, Dotti G.

Cancer J. 2014 Mar-Apr;20(2):112-8. doi: 10.1097/PPO.0000000000000031. Review.

29.

Genetic modification of cytotoxic T lymphocytes to express cytokine receptors.

Perna SK, Savoldo B, Dotti G.

Methods Mol Biol. 2014;1139:189-200. doi: 10.1007/978-1-4939-0345-0_17.

PMID:
24619681
30.

Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.

Kennedy-Nasser AA, Ku S, Castillo-Caro P, Hazrat Y, Wu MF, Liu H, Melenhorst J, Barrett AJ, Ito S, Foster A, Savoldo B, Yvon E, Carrum G, Ramos CA, Krance RA, Leung K, Heslop HE, Brenner MK, Bollard CM.

Clin Cancer Res. 2014 Apr 15;20(8):2215-25. doi: 10.1158/1078-0432.CCR-13-3205. Epub 2014 Feb 26.

31.

Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.

Parmar S, Liu X, Tung SS, Robinson SN, Rodriguez G, Cooper LJ, Yang H, Shah N, Yang H, Konopleva M, Molldrem JJ, Garcia-Manero G, Najjar A, Yvon E, McNiece I, Rezvani K, Savoldo B, Bollard CM, Shpall EJ.

Cytotherapy. 2014 Jan;16(1):90-100. doi: 10.1016/j.jcyt.2013.07.009. Epub 2013 Oct 26.

32.

T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.

Geldres C, Savoldo B, Hoyos V, Caruana I, Zhang M, Yvon E, Del Vecchio M, Creighton CJ, Ittmann M, Ferrone S, Dotti G.

Clin Cancer Res. 2014 Feb 15;20(4):962-71. doi: 10.1158/1078-0432.CCR-13-2218. Epub 2013 Dec 13.

33.

Design and development of therapies using chimeric antigen receptor-expressing T cells.

Dotti G, Gottschalk S, Savoldo B, Brenner MK.

Immunol Rev. 2014 Jan;257(1):107-26. doi: 10.1111/imr.12131. Review.

34.

Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition.

Perna SK, Pagliara D, Mahendravada A, Liu H, Brenner MK, Savoldo B, Dotti G.

Clin Cancer Res. 2014 Jan 1;20(1):131-9. doi: 10.1158/1078-0432.CCR-13-1016. Epub 2013 Oct 4. Erratum in: Clin Cancer Res. 2014 Aug 15;20(16):4413.

35.

Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment.

Robinson SN, Thomas MW, Simmons PJ, Lu J, Yang H, Parmar S, Liu X, Shah N, Martín-Antonio B, Bollard C, Dotti G, Savoldo B, Cooper LJ, Najjar A, Rezvani K, Kaur I, McNiece IK, Champlin RE, Miller LP, Zweidler-McKay PA, Shpall EJ.

Cytotherapy. 2014 Jan;16(1):84-9. doi: 10.1016/j.jcyt.2013.07.003. Epub 2013 Oct 1.

36.

Chimeric antigen receptors (CARs) from bench-to-bedside.

Savoldo B, Dotti G.

Immunol Lett. 2013 Sep-Oct;155(1-2):40-2. doi: 10.1016/j.imlet.2013.09.014. Epub 2013 Sep 27. Review.

37.

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.

Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, Barrett AJ, Ito S, Shpall EJ, Krance RA, Kamble RT, Carrum G, Hosing CM, Gee AP, Mei Z, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Bollard CM, Dotti G.

Blood. 2013 Oct 24;122(17):2965-73. doi: 10.1182/blood-2013-06-506741. Epub 2013 Sep 12. Erratum in: Blood. 2014 May 22;123(21):3364.

38.

CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma.

Casucci M, Nicolis di Robilant B, Falcone L, Camisa B, Norelli M, Genovese P, Gentner B, Gullotta F, Ponzoni M, Bernardi M, Marcatti M, Saudemont A, Bordignon C, Savoldo B, Ciceri F, Naldini L, Dotti G, Bonini C, Bondanza A.

Blood. 2013 Nov 14;122(20):3461-72. doi: 10.1182/blood-2013-04-493361. Epub 2013 Sep 9.

39.

The immunogenicity of virus-derived 2A sequences in immunocompetent individuals.

Arber C, Abhyankar H, Heslop HE, Brenner MK, Liu H, Dotti G, Savoldo B.

Gene Ther. 2013 Sep;20(9):958-62. doi: 10.1038/gt.2013.25. Epub 2013 May 23.

40.

Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.

Weber G, Gerdemann U, Caruana I, Savoldo B, Hensel NF, Rabin KR, Shpall EJ, Melenhorst JJ, Leen AM, Barrett AJ, Bollard CM.

Leukemia. 2013 Jul;27(7):1538-47. doi: 10.1038/leu.2013.66. Epub 2013 Mar 1.

41.

Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease.

Chakraborty R, Mahendravada A, Perna SK, Rooney CM, Heslop HE, Vera JF, Savoldo B, Dotti G.

Haematologica. 2013 Apr;98(4):533-7. doi: 10.3324/haematol.2012.076430. Epub 2012 Dec 14.

42.

Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients.

Engels EA, Savoldo B, Pfeiffer RM, Costello R, Zingone A, Heslop HE, Landgren O.

Transplantation. 2013 Feb 15;95(3):519-26. doi: 10.1097/TP.0b013e318274ab63.

43.

Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.

Ramos CA, Narala N, Vyas GM, Leen AM, Gerdemann U, Sturgis EM, Anderson ML, Savoldo B, Heslop HE, Brenner MK, Rooney CM.

J Immunother. 2013 Jan;36(1):66-76. doi: 10.1097/CJI.0b013e318279652e.

44.

Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma.

Perna SK, De Angelis B, Pagliara D, Hasan ST, Zhang L, Mahendravada A, Heslop HE, Brenner MK, Rooney CM, Dotti G, Savoldo B.

Clin Cancer Res. 2013 Jan 1;19(1):106-17. doi: 10.1158/1078-0432.CCR-12-2143. Epub 2012 Nov 13.

45.

Cancer battlefield: six characters in search of an author.

Huye L, Savoldo B.

Immunotherapy. 2012 Aug;4(8):753-5. doi: 10.2217/imt.12.77. No abstract available.

PMID:
22947001
46.

Genetic modification of human T lymphocytes for the treatment of hematologic malignancies.

Hoyos V, Savoldo B, Dotti G.

Haematologica. 2012 Nov;97(11):1622-31. doi: 10.3324/haematol.2012.064303. Epub 2012 Aug 28. Review.

47.

Cytotoxic T lymphocytes for the treatment of viral infections and posttransplant lymphoproliferative disorders in transplant recipients.

Pagliara D, Savoldo B.

Curr Opin Infect Dis. 2012 Aug;25(4):431-7. doi: 10.1097/QCO.0b013e3283551dd3. Review.

PMID:
22614521
48.

Changes in chemokine receptor expression of regulatory T cells after ex vivo culture.

Chakraborty R, Rooney C, Dotti G, Savoldo B.

J Immunother. 2012 May;35(4):329-36. doi: 10.1097/CJI.0b013e318255adcc.

49.

EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors.

White RE, Rämer PC, Naresh KN, Meixlsperger S, Pinaud L, Rooney C, Savoldo B, Coutinho R, Bödör C, Gribben J, Ibrahim HA, Bower M, Nourse JP, Gandhi MK, Middeldorp J, Cader FZ, Murray P, Münz C, Allday MJ.

J Clin Invest. 2012 Apr;122(4):1487-502. doi: 10.1172/JCI58092. Epub 2012 Mar 12.

50.

Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγ(null) mice.

Robinson SN, Simmons PJ, Thomas MW, Brouard N, Javni JA, Trilok S, Shim JS, Yang H, Steiner D, Decker WK, Xing D, Shultz LD, Savoldo B, Dotti G, Bollard CM, Miller L, Champlin RE, Shpall EJ, Zweidler-McKay PA.

Exp Hematol. 2012 Jun;40(6):445-56. doi: 10.1016/j.exphem.2012.01.015. Epub 2012 Feb 2.

Supplemental Content

Loading ...
Support Center